您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录 护理专家
首页
  • 夏良平

    职务:综合科副主任
    职称:肿瘤学博士,主任医师,博士生导师
    专长:主要从事肿瘤综合治疗;肠癌、肺癌、乳腺癌等常见肿瘤的内科治疗(尤其是靶向治疗);VIP病人保健和管理。
      夏良平,男,1969年8月9日出生,安徽省怀宁县人。肿瘤学博士,主任医师,博士生导师,中山大学肿瘤防治中心综合科科室副主任。主要从事肿瘤综合治疗;肠癌、肺癌、乳腺癌等常见肿瘤的内科治疗(尤其是靶向治疗);VIP病人保健和管理。至今发表科研论文146篇,其中第一作者/通讯作者95篇(包括56篇SCI论文),包括J Clin Invest;Nat Commun;Clin Cancer Res;J Immunother Cancer;Mol Ther;JNCCN;Int J Cancer;Aging;J Transl Med;Sci Rep等杂志。主持14项科研基金,包括3项国家自然科学基金。
      另外,承担全院“静脉输液港植入术”,至今有近1000例植入术经验,并成功举办四期“静脉输液港植入术和护理技术培训班”的广东省继续教育项目和一届“海峡两岸输液港技术论坛”。

    学习工作经历:
    1989~1994 安徽医科大学医学系
    1994~1996 安徽医科大学第一附属医院外科
    1996~1999 中山大学附属第一医院(硕士生)
    1999~2002 中山大学附属肿瘤医院(博士生)
    2002~     中山大学附属肿瘤医院综合科

    社会任职
    1.广东省健康管理学会肿瘤防治专业委员会,主任委员
    2.广东省健康管理学会干细胞与再生医学专委会,副主任委员
    3.广东省抗癌协会靶向与个体化治疗专业委员会,常委
    4.广东省抗癌协会化疗专业委员会,委员
      夏良平,男,1969年8月9日出生,安徽省怀宁县人。肿瘤学博士,主任医师,博士生导师,中山大学肿瘤防治中心综合科科室副主任。主要从事肿瘤综合治疗;肠癌、肺癌、乳腺癌等常见肿瘤的内科治疗(尤其是靶向治疗);VIP病人保健和管理。至今发表科研论文146篇,其中第一作者/通讯作者95篇(包括56篇SCI论文),包括J Clin Invest;Nat Commun;Clin Cancer Res;J Immunother Cancer;Mol Ther;JNCCN;Int J Cancer;Aging;J Transl Med;Sci Rep等杂志。主持14项科研基金,包括3项国家自然科学基金。
      另外,承担全院“静脉输液港植入术”,至今有近1000例植入术经验,并成功举办四期“静脉输液港植入术和护理技术培训班”的广东省继续教育项目和一届“海峡两岸输液港技术论坛”。

    学习工作经历:
    1989~1994 安徽医科大学医学系
    1994~1996 安徽医科大学第一附属医院外科
    1996~1999 中山大学附属第一医院(硕士生)
    1999~2002 中山大学附属肿瘤医院(博士生)
    2002~     中山大学附属肿瘤医院综合科

    科研经历:
    一.基金
    (一)第一负责人基金
    1.中山大学肿瘤防治中心特支计划:临床科学家项目,2019,主持
    2.中山大学肿瘤防治中心308项目:二甲双胍联合FOLFIRI二线治疗非糖尿病RAS突变型转移性结直肠癌的多中心、单臂Ⅱ期临床研究,2019,主持
    3.国家自然科学基金项目(81572409):LDH预测bevacizumab治疗转移性结直肠癌疗效的机制及新靶点的探索性研究。(2015)
    4.国家自然科学基金项目(81272641):同步干预2,3-DPG和PKM2在提高Bevacizumab治疗肠癌疗效中的关键作用。(2012)
    5.国家自然科学基金项目(81071872):Cetuximab通过下调SGLT1诱导肠癌细胞自噬性死亡是其抗肿瘤和增敏化疗的新机制。(2010)
    6.广东省自然科学基金(2015A030313010):AMPK/mTOR通路在cetuximab诱发肠癌细胞自噬过程中的作用与意义。(2015年)
    7.广州市科技计划项目(1563000305):Adenosine联合siRNA-PKM2克服bevacizumab的“促癌作用”并提高其杀伤肠癌细胞能力的研究。(2015)
    8.广东省科技计划项目(2011B061300069):3-MA阻断肺癌H460细胞自噬而提高Cetuximab+DDP抗肿瘤效应。(2011)
    9.广东省科技计划项目(2008B06060029):siRNA抑制eIF4E后喉癌细胞株Hep2蛋白质表达谱变化的研究。(2008年)
    10.广东省自然科学基金(9151008901000102):不同p53背景下VX-680联合Taxol杀伤鼻咽癌细胞的疗效差异。(2009年)
    11.广东省卫生厅项目:乳腺癌中Aurora-A表达与含Taxanes诱导化疗方案疗效关系的研究。(2008)。
    12.“重大新药创新”科技重大专项基金:自噬性细胞死亡在Cetuximab联合Oxaliplatin/Irinotecan方案治疗肠癌中的作用。(2008ZX09312-002). 
    13.广东省卫生厅基金:利用18FDG探测喉癌手术创面中肿瘤残留状况的研究。(B2004058)
    14.中山大学肿瘤防治中心基金:利用18FDG探测喉癌手术创面中肿瘤残留状况的研究。(303041080562)。

    (二)第二负责人基金
    15.广东省科技计划项目(2010B031600317):Cetuximab 下调SGLT1诱导肠癌细胞自噬为增敏Irinotecan的新机制(2010)。
    16.广东省卫生厅基金(C2011019):结直肠癌患者标准化与个体化治疗相结合体系的建立与优化(2012)。
    17.广东省科技计划项目(20012137-C30305):喉鳞癌手术切缘eIF4E、P53研究在喉功能保全性治疗中的应用。(2001)。

    (三)第三负责人基金
    18. 高等学校博士学科点专项科研基金(2000305):同步高表达PFP、GrB 基因的喉癌TIL抗肿瘤作用的研究。(2000)。

    二.文章
    (一)第一作者/通讯作者论文(SCI)
    1.Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P, Huang P, Chen S, Li W, Xia LP(共同通讯), Xia X. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019 Aug 13;130. pii: 127471. doi: 10.1172/JCI127471.
    2.Guo G, Wang Y, Zhou Y, Quan Q, Zhang Y, Wang H, Zhang B, Xia L. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother Cancer. 2019 Jul 12;7(1):179. doi: 10.1186/s40425-019-0656-3.
    3.Guo GF, Wang YX, Zhang YJ, Chen XX, Lu JB, Wang HH, Jiang C, Qiu HQ, Xia LP. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. World J Gastroenterol. 2019 Apr 21;25(15):1840-1853. doi: 10.3748/wjg.v25.i15.1840.
    4.Jiang C, Wang F, Guo G, Dong J, Liu S, He W, Zhang B, Xia L.Metastatic lymph node ratio as a prognostic indicator in patients with stage IV colon cancer undergoing resection.J Cancer. 2019 Jun 2;10(11):2534-2540.
    5.Kong P, Wang J, Song Z, Liu S, He W, Jiang C, Xie Q, Yang L, Xia X, Xia L.Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.J Cancer. 2019 Apr 5;10(7):1745-1754
    6.Wu RY, Kong PF, Xia L(共一), Huang Y, Li ZL, Tang YY, Chen Y, Li X, Senthilkumar R, Zhang HL, Sun T, Xu XL, Yu Y, Mai J, Peng XD, Yang D, Zhou LH, Feng GK, Deng R, Zhu XF. Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.Clin Cancer Res. 2019 Apr 2. pii: clincanres.2840.2018. doi: 10.1158/1078-0432.CCR-18-2840. [Epub ahead of print]
    7.Quan Q, Zhu M, Liu S, Chen P, He W, Huang Y, Rong Y, Qiu H, Zhang B, Xia L. Positive impact of the negative lymph node count on the survival rate of stage III colon cancer with pN1 and right-side disease. J Cancer. 2019 Jan 29;10(4):1052-1059.
    8.Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L.Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.Oncol Lett. 2019 Feb;17(2):2335-2343. 
    9.Yang L, Yang X, He W, Liu S, Jiang C, Xie K, Peng K, You Y, Zhang B, Xia L.Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study.Aging (Albany NY). 2018 Dec 28. doi: 10.18632/aging.101700. [Epub ahead of print]
    10.Yang L, He W, Xie Q, Liu S, Kong P, Jiang C, Zhang B, Xia L. Brain metastases in newly diagnosed colorectal cancer: a population-based study.Cancer Manag Res. 2018 Nov 15;10:5649-5658.
    11.Wang F, He W, Jiang C, Guo G, Ke B, Dai Q, Long J, Xia L. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.BMC Cancer. 2018 Nov 12;18(1):1102. doi: 10.1186/s12885-018-4842-3.
    12.Guo G, Chen X, He W, Wang H, Wang Y, Hu P, Rong Y, Fan L, Xia L.Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data.PLoS One. 2018 Dec 4;13(12):e0208547.
    13.Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, Kong PF, Liu SS, Chen HT, Yang YZ, Wang D, Yang L, Xia LP.The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor.J Transl Med. 2018 Oct 4;16(1):273. 
    14.Jiang C, Huang YH, Lu JB, Yang YZ, Rao HL, Zhang B, He WZ, Xia LP.Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer.Cancer Manag Res. 2018 Sep 17;10:3589-3597.
    15.Yang L, Xiong Z, Xie QK, He W, Liu S, Kong P, Jiang C, Xia X, Xia L.Second primary colorectal cancer after the initial primary colorectal cancer.BMC Cancer. 2018 Sep 27;18(1):931. 
    16.He WZ, Hu WM, Kong PF, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Qiu HJ, Zhang B, Zhang HZ, Xia LP.Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value.J Cancer. 2018 Aug 6;9(17):3093-3100. 
    17.Yang L, Xiong Z, He W, Xie K, Liu S, Kong P, Jiang C, Guo G, Xia L. Proximal shift of colorectal cancer with increasing age in different ethnicities.Cancer Manag Res. 2018 Aug 15;10:2663-2673.
    18.He WZ, Yang QX, Xie JY, Kong PF, Hu WM, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP.Association of low skeletal muscle index with increased systematic inflammatory responses and interferon γ-induced protein 10 levels in patients with colon cancer.Cancer Manag Res. 2018 Aug 7;10:2499-2507
    19.Liu SS, Yang YZ, Jiang C, Quan Q, Xie QK, Wang XP, He WZ, Rong YM, Chen P, Yang Q, Yang L, Zhang B, Xia XJ, Kong PF, Xia LP.Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.J Transl Med. 2018 Jul 13;16(1):195. doi: 10.1186/s12967-018-1570-z.
    20.He WZ, Xie QK, Hu WM, Kong PF, Yang L, Yang YZ, Jiang C, Yin CX, Qiu HJ, Zhang HZ, Zhang B, Xia LP.An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients.Cancer Manag Res. 2018 Jun 18;10:1597-1604.
    21.Xie QK, He WZ, Hu WM, Yang L, Jiang C, Kong PF, Yang YZ, Yang Q, Zhang HZ, Zhang B, Xia LP.Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality.Cancer Manag Res. 2018 May 30;10:1365-1375.
    22.Yang L, Xiong Z, Xie Q, He W, Liu S, Kong P, Jiang C, Guo G, Xia L. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer. 2018 May 11;18(1):558. doi: 10.1186/s12885-018-4431-5.
    23.Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L.Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.J Cancer. 2018 Jan 1;9(1):205-212.
    24.Wang H, Peng R, Chen X, Jia R, Huang C, Huang Y, Xia L(共同通讯), Guo G. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer. Oncol Lett. 2018 Apr;15(4):5553-5560.
    25.Yang L, He W, Kong P, Jiang C, Yang Q, Xie Q, Xia LP. Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers. BMC Cancer. 2017 Dec 20;17(1):873. doi: 10.1186/s12885-017-3862-8.
    26.Yang L, He W, Yang Q, Kong P, Xie Q, Jiang C, Zhang B, Xia LP.Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer.Oncotarget. 2017 Oct 12;8(58):99136-99149. 
    27.Kong P, Wu R, Lan Y, He W, Yang C, Yin C, Yang Q, Jiang C, Xu D, Xia L.Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis.J Cancer. 2017 Sep 16;8(16):3296-3308.
    28.Yang L, Xia L(共同第一), Wang Y, He S, Chen H, Liang S, Peng P, Hong S, Chen Y.Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma.BMC Cancer. 2017 Sep 6;17(1):628. 
    29.Jiang C, Liu S, He W, Zhang B, Xia L. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. J Cancer. 2017 May 12;8(8):1410-1416.
    30.Quan Q, Huang Y, Chen Q, Qiu H, Hu Q, Rong Y, Li T, Xia L, Zhang B.Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol. 2017 Apr;10(2):288-294. doi: 10.1016/j.tranon.2017.01.006. Epub 2017 Mar 2.
    31.He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP.Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J Cancer. 2017 Feb 10;8(3):388-394.
    32.Kong P, Zhu X, Geng Q, Xia L(共同第一), Sun X, Chen Y, Li W, Zhou Z, Zhan Y, Xu D.The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer.Mol Ther. 2017 Feb 18. pii: S1525-0016(17)30020-5. doi: 10.1016/j.ymthe.2017.01.013. [Epub ahead of print]
    33.Kong P, Wu R, Liu X, Liu J, Chen S, Ye M, Yang C, Song Z, He W, Yin C, Yang Q, Jiang C, Liao F, Peng R, Zhou Z, Xu D, Xia L.The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis.J Cancer. 2016;7(15):2247-2257.
    34.Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L.The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer. 2016 Sep 13;7(13):1901-1906.
    35.Kong P, Wu R, Yang C, Geng Q, Liu J, Chen S, Liu X, Ye M, He W, Yang Q, Xia L, Xu D. Prognostic Impact of the Signet Ring Cell Type in Node-Negative Gastric Cancer. Sci Rep. 2016;6:26313. doi: 10.1038/srep26313.
    36.Yang L, Xia L, Wang Y, Hong S, Chen H, Liang S, Peng P, Chen Y. Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis. PLoS One. 2016 Jul 11;11(7):e0158853. doi: 10.1371/journal.pone.0158853. eCollection 2016.
    37.He WZ, Rong YM, Jiang C, Liao FX, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.Chin J Cancer. 2016;35(1):58. doi: 10.1186/s40880-016-0120-4.
    38.Yang Q, Liao F, Huang Y, Jiang C, Liu S, He W, Kong P, Zhang B, Xia L. Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients. Oncotarget. 2016 Apr 12;7(15):21034-45.
    39.Jiang C, Hu WM, Liao FX, Yang Q, Chen P, Rong YM, Guo GF, Yin CX, Zhang B, He WZ, Xia LP. Elevated preoperative neutrophil-to-lymphocyte ratio is associated with poor prognosis in gastrointestinal stromal tumor patients. Onco Targets Ther. 2016;9:877-83. 
    40.Liao F, He W, Jiang C, Yin C, Guo G, Chen X, Qiu H, Rong Y, Zhang B, Xu D, Xia L. A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C.Onco Targets Ther. 2015;8:3135-3142.
    41.Yang Q, Yin C, Liao F, Huang Y, He W, Jiang C, Guo G, Zhang B, Xia L.Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.Onco Targets Ther. 2015;8:2407-13. 
    42.Chen ZY, He WZ, Peng LX, Jia WH, Guo RP, Xia LP(共同通讯), Qian CN.A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients.Int J Cancer. 2015 Feb 1;136(3):584-92. 
    43.He WZ, Yin CX, Jiang C, Guo GF, Rong RM, Qiu HJ, Chen XX, Zhang B, Xia LP. Prognostic Model Built on Blood-based Biomarkers in Patients with Metastatic Colorectal Cancer. Asian Pac J Cancer Prev. 2014; ;15(17):7327-31.
    44.Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014;7:1415-22.
    45.Jiang C, Liao FX, Rong RM, Yang Q, Yin CX, He WZ, Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pac J Cancer Prev. 2014;15(13):5493-8.
    46.He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, Chen XX, Rong RM, Zhang B, Xia LP. γ-Glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013 Aug;15(8):e443-52. 
    47.He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L. Initial Neutrophil Lymphocyte Ratio Is Superior To Platelet Lymphocyte Ratio As An Adverse Prognostic and Predictive Factor In Metastatic Colorectal Cancer. Medical Oncology. 2013 Mar;30(1):439.
    48.Wang F, He W, Qiu H, Wang X, Guo G, Chen X, Rong Y, Zhou F, Yin C, Yuan Z, Xia L. Lymph Node Ratio and pN Staging Show Different Superiority As Prognostic Predictors Depending on the Number of Lymph Nodes Dissected in Chinese Patients with Luminal A Breast Cancer. Clin Breast Cancer. 2012 Dec;12(6):404-11.
    49.Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF, Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP.Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer.Cancer Biol Med. 2012 Mar;9(1):38-43.
    50.Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Wang F, Chen XX, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol. 2011; 17(43): 4839-4846.
    51.Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP*.Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity correlates with increase of Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 2011 Dec;28(4):1302-7.
    52.Xia LP, Qiu HJ, Chen XX, Hu PL, Guo GF, Wang F, Zhou FF, He WZ, Zhang B, Zhang L. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Med Oncol. 2011 Dec;28 Suppl 1:570-6.
    53.Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F.Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol. 2011 Dec;28 Suppl 1:197-203.(共同通讯)
    54.Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, Wang F. Changes in Therapeutic Strategies in Chinese Male Patients with Breast Cancer: 40 Years of Experience in a Single Institute. Breast. 2010;19(6):450-5.
    55.Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352.
    56.Zhang B, He WZ, Zhou FF, Guo GF, Jiang C, Yin CX, Chen XX, Qiu HJ, Rong RM, Xia LP. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy. 2013, 2:108. doi:10.4172/2167-7700.1000108

    第一作者/通讯作者论文(非SCI)
    57.Yin CX, Jiang C, Liao FX, Rong RM, He WZ,Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP.The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting. Chinese-German Journal of Clinical Oncology. 2014;13(4): 169-173.
    58.Qiu HJ, He WZ, Yin CX, Guo GF, Wang F, Zhou FF, Jiang C, Xia LP. The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer. Chinese-German Journal of Clinical Oncology. 2012;11(10): 585-591.
    59.Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF , Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biology & Medicine. 2012;9(1):38-43.
    60.Wang F, Guo GF, Qiu HJ, Chen XX, Hui PL, Zhou FF, He WZ, Zhang B, Xia LP. Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer. Clin Oncol Cancer Res. 2011; 8(4): 235–241
    61.Qiu HJ, He WZ, Chen XX, Guo GF, Wang F, Zhou FF, Xia LP. The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. Chinese-German Journal of Clinical Oncology.2011;10(11): 621-625.
    62.Zhou FF,  Huang R, Jiang J, Wang F,  He WZ, Guo GF, Xia LP. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer. Chinese-German Journal of Clinical Oncology.2011;10(6): 311-316.
    63.Qiu HJ, Wang F, Guo GF, Zhou FF, He WZ, Xia LP. Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis. Chinese-German Journal of Clinical Oncology. 2011;10(3): 134-139.
    64.Wang F, Xia LP, Guo GF, Qiu HJ, Zhou FF, He WZ. The Pooled Analysis of Single Gemcitabine For Non-Small Cell Lung Cancer (NSCLC) Patients With Elderly Age. Chinese-German Journal of Clinical Oncology.2010;9(12):683-687.
    65.丘惠娟,夏良平,汪芳,郭桂芳,周菲菲,张蓓,张力.Cetuximab联合一线和非一线化疗方案治疗16 例非小细胞肺癌近期疗效及其疗效差异.南方医科大学学报.2010;30(11):2423-2426.
    66.Wang F, Xia LP, Guo GF, et al. Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with Non-small cell lung cancer: a report of 6 cases. Chinese-German Journal of Clinical Oncology.2010;9(9):502-506. 
    67.Xia LP, Yuan ZY, Wang X, et al. Characteristics of Chinese Male Patients with Breast Cancer: Summary of the Published Papers. Chinese-German Journal of Clinical Oncology.2010;9(6):311-315.
    68.周菲菲,夏良平,王曦,郭桂芳,戎煜明,丘惠娟,张蓓.72例男性乳腺癌患者临床病理特征和预后分析.中国肿瘤临床. 2010;37(22):1296-1299.
    69.Xia LP, Rong YM, Guo GF, et al. The summary of efficacy of cetuximab combination with chemotherapy in NSCLC first-line setting: based on publication. Chinese-German Journal of Clinical Oncology.2010;9(3):137-141.
    70.丘惠娟,夏良平,徐瑞华,张蓓,郭桂芳,戎煜明,周菲菲,汪芳.含Cetuximab方案治疗10例胃癌和食管癌的近期疗效分析.肿瘤学杂志.2010;16(4):294-297.
    71.周菲菲,夏良平,王曦,郭桂芳,戎煜明,丘惠娟,张蓓.影响男性乳腺癌预后的多因素分析—单中心72例临床资料总结.癌症.2010;29(2):196-201.
    72.夏良平,张力,张蓓,郭桂芳,丘惠娟,戎煜明,汪桃利,周菲菲.Cetuximab联合化疗治疗非小细胞肺癌近期疗效分析—附2例报告及文献综述.肿瘤学杂志.2010;16(2):133-138.
    73.Xia LP, Guo GF,Zhang B, et al. Short-term Efficacy of Cetuximab-contained Regimen on Patients with Advanced Gastrointestinal (Noncolorectal) Cancer: Experiences of 16 Patients in Single Institute. Chinese-German Journal of Clinical Oncology.2009; 8(11):669-674.
    74.Xia LP, Guo GF,Qiu HJ, et al. Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. Chinese-German Journal of Clinical Oncology.2009;8(9):526-530.
    75.夏良平, 张蓓, 郭桂芳, 等. 鼻咽癌放疗后残留和复发颈淋巴结的分布规律. 中山大学学报(医学科学版).2009;30(supple 4):199-202.
    76.夏良平,张蓓, 刘茂珍, 等.Cetuximab联合放疗或化疗治疗11例头颈恶性肿瘤近期疗效分析.癌症.2009.28(9):977-982.
    77.Xia LP, Zeng ZY, Guo ZM, Guo GF, Zhang B, Qiu HJ, Zhou FF. Neck dissection for recurrent and persistent lymph nodes of nasopharyngeal carcinoma after radiotherapy: effect and choice. Chinese-German Journal of Clinical Oncology.2009;8(2):81-85.
    78.夏良平,张蓓,丘惠娟,等.鼻咽癌放疗后颈淋巴结残留与复发的疗效差异.中山大学学报(医学科学版).2008;29(supple 3):41-44.
    79.夏良平, 李秀英, 张诠, 等. 人穿孔素扩增与表达分析. 肿瘤学杂志,2006;12(3):188-190.
    80.华辉, 陈静静, 夏良平, 等. 肿瘤浸润性T淋巴细胞ζ链异常表达在舌癌预后中的价值. 中国肿瘤. 2009,18(40):304-307.
    81.夏良平, 曾宗渊, 陈直华, 等. 鼻咽癌放疗后颈淋巴结复发和残留的外科治疗. 中华耳鼻咽喉科杂志, 2005,40(2):95-99.
    82.Xia LP, Zeng ZY, Guo ZM, et al . The Value Of Pathological and Molecular Margins To Direct The Postoperative Treatments Of Laryngeal Carcinoma. The Chinese-German Journal of Clinical Ocology. 2005,4(1):56-60.
    83.夏良平,曾宗渊,许光普,等. 喉鳞癌原发灶和切缘中P53蛋白表达对术后治疗的指导价值.中华肿瘤杂志, 2003,25(6):558-561.
    84.夏良平,许光普,曾宗渊,等. 喉鳞癌手术切缘eIF4E蛋白表达与预后的关系.中华耳鼻咽喉科杂志, 2003,38(2):139-142.
    85.夏良平, 陈直华,陈忠平,等. 颅面联合进路切除颅底恶性肿瘤16例临床总结. 中国神经肿瘤杂志,2004,2(1):62-66.
    86.夏良平, 曾宗渊, 郭朱明, 等.喉鳞癌原发灶及无瘤手术切缘组织p53蛋白表达及其与预后的研究. 癌症.2003; 22(1):77-82.
    87.夏良平,曾宗渊,许光普,等.喉鳞癌病理学阴性切缘中eIF4E和P53蛋白检测及其意义.肿瘤, 2003,23(6):505-507.
    88.夏良平,曾宗渊,郭朱明,等. 喉癌术后颈淋巴结复发的多因素分析. 中华临床医学实践杂志.2003;2(12):1057-1060.
    89.夏良平,曾宗渊,许光普,等. 喉鳞癌原发灶中eIF4E和P53蛋白表达特征及意义. 临床耳鼻咽喉科杂志.2003,17(增刊):35-37.
    90.夏良平,曾宗渊,陈福进,等.保留喉功能的治疗方法在喉癌T3病例中的应用探讨. 癌症, 2001,20(5):511-514.
    91.夏良平, 李添应, 陈明远,等. 鼻息肉患者鼻息肉组织及鼻分泌物中白细胞介素-5的测定.耳鼻咽喉-头颈外科, 2001, 8(1):38-41.
    92.夏良平, 曾宗渊, 魏茂文, 等. 影响喉癌生存率诸因素的单因素和多因素分析. 中国肿瘤.2002; 11(11):655-657. 
    93.夏良平, 曾宗渊, 曾敬,等.eIF4E及其ser-209磷酸化蛋白在喉鳞癌中表达特征及意义. 中国肿瘤2004,13(3):171-173.
    94.夏 良 平, 曾 宗 渊, 郭朱明,等. 喉癌三种不同颈淋巴结转移状态者生存率分析. 肿瘤. 2004,24(4):388-391.
    95.夏良平,曾宗渊,陈直华,等.部分喉切除术中影响切缘结果的因素分析.肿瘤学杂志. 2004,10(4):220-222.

    (二)非第一作者论文
    96.Chen P, Zhang B, Guo GF, Xia LP, Qiu HJ. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. Chinese-German Journal of Clinical Oncology.2014.13(5):229-234.
    97.Sun T, Li D, Wang L, Xia L, Ma J, Guan Z, Feng G, Zhu X. c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide-induced autophagy in human nasopharyngeal carcinoma cells. J Transl Med. 2011 Sep 26;9:161.
    98.Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway.Mol Cancer Ther. 2009;8(4):873-882.(IF=5.003)
    99.Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, Zhu XF.PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation.Oncogene.
    Oncogene. 2011 Feb 24;30(8):944-55.
    100.Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q.Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.Mol Cancer. 2009 Nov 5;8:95. (IF=5.362)
    101.Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q.Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells.Carcinogenesis. 2008;29(10):1930-1937. (IF=4.93)
    102.郭桂芳,夏良平,徐瑞华,陈徐贤,汪 芳,何文卓,姜文奇.西妥昔单抗联合化疗治疗晚期结直肠癌的生存分析及KRAS对疗效的影响. 中山大学学报医学科学版. 2011;32(5): 637-643.
    103.郭桂芳,夏良平,丘惠娟,等.西妥昔单抗联合化疗治疗102例K-ras状态不明晚期结直肠癌的疗效.中华肿瘤杂志.2010;32(10):777-781.
    104.徐大志, 夏良平, 林桐榆, 等. 磷酸化的哺乳动物雷帕霉素靶蛋白在胃癌组织中的表达.中山大学学报医学科学版. 2009;30(3): 304-307. 
    105.李秀英, 夏良平, 赖延东.人PFP、GrB共表达诱导喉癌Hep-2细胞凋亡的研究.免疫学杂志,2009;25(2):150-157.
    106.李秀英,夏良平, 赖延东.PFP、GrB的共表达杀伤人喉癌Hep-2细胞的体外研究.现代免疫学. 2008; 28(3):224-228. 
    107.李秀英, 夏良平, 赖延东. PFP、GrB真核共表达载体的构建及表达分析.中国免疫学杂志,2008,24(6):492-495.
    108.陈明远, 夏良平, 陈直华,等.植人式静脉输液港不同植人术式在恶性肿瘤患者中的应用. 中山大学学报(医学科学版).2007;28(3S):145-147.
    109.叶石敦, 夏良平, 赖延东. 重组人颗粒酶B对胃癌细胞增殖的影响.山东医药,2006;46(6):15-16.
    110.郭桂芳,夏良平,张蓓,姜文奇,丘惠娟,刘茂珍,胡丕丽,陈徐贤,周菲菲.西妥昔单抗联合化疗治疗53例晚期结直肠癌的疗效. 癌症.2009;28(12):1317-1323.
    111.曾宗渊,夏良平,陈福进,等.术中留取切缘标本对早期喉癌患者术后治疗的指导价值. 中华耳鼻咽喉科杂志, 2001,36(4):250-253.
    112.李添应, 夏良平, 陈明远,等. 白细胞介素-5及嗜酸性粒细胞在鼻息肉中的相关性研究. 临床耳鼻咽喉科杂志, 2000, 14(11):488-490.
    113.李添应, 夏良平, 孟庆翔, 等.nm23-H1基因在鼻腔鼻窦内翻性乳头状瘤及其癌变组织中的表达. 临床耳鼻咽喉科学杂志. 2004,18(2):86-87.
    114.曾宗渊,夏良平,郭朱明,等.喉癌治疗方法的选择和失败原因分析. 癌症,2001, 20(11):1012-1015. 
    115.李秀英, 赖延东, 夏良平, 等. 人颗粒酶B基因的克隆、蛋白纯化及表达分析. 现代免疫学,.2004,24(6):486-489.
    116.李秀英, 赖延东, 夏良平, 等.人穿孔素基因真核表达载体的构建与表达分析. 免疫学杂志, 2005,21(6):546
    117.李添应, 邱前辉, 夏良平.功能性内窥镜鼻窦手术对嗅觉及嗅粘膜上皮形态的影响. 中山医科大学学报, 2000,21(6):473-477
    118.许光普, 曾宗渊, 夏良平, 等. 部分喉切除术切缘病理学检查对术后治疗及预后估计的意义. 癌症,2002,21(2):200-203.
    119.郭朱明, 曾宗渊, 夏良平,等.口底鳞状细胞癌转移性颈淋巴结分布特点及处理的探讨. 癌
    120.杨安奎, 陈福进,曾宗渊, 夏良平. 全喉切除术前喉裂开探查对病人预后的影响. 中国肿瘤, 2001,10(9):550-552.
    121.郭朱明,曾宗渊,夏良平,等. 微波固化在口腔癌中的临床应用—附96例临床总结. 癌症.2003; 22(1):71-76.
    122.黄湛, 曾宗渊, 官梅, 夏良平. iNOS和bFGF在声门上喉鳞癌中的表达及意义. 癌症.2002; 21(9 ): 961-964.
    123.黄湛, 曾宗渊, 彭汉伟, 夏良平,等.声门上喉鳞癌组织中诱导型一氧化氮合酶和碱性成纤维细胞生长因子表达与预后的关系.癌症. 2003,22(9):978-981.
    124.张诠, 曾宗渊, …夏良平.等.微波固化治疗口腔癌的疗效分析. 癌症, 2001, 20(10):1100-1103.
    125.郭朱明, 曾宗渊, 夏良平,等.口底鳞状细胞癌转移性颈淋巴结分布特点及处理的探讨. 癌症.2002; 21(9):979-982.
    126.曾宗渊,张 诠,…夏良平.微波固化与外科手术治疗口底癌的疗效比较. 中华耳鼻咽喉科杂志, 2002,37(2):90-94.
    127.许光普, 曾宗渊, 陈福进,… 夏良平.等. 新辅助化疗治疗晚期喉癌及喉咽癌的近期疗效评定. 临床肿瘤学杂志2002;7(6):413-415.

    (三)综述及病例报道
    128.江畅, 夏良平. 肿瘤干细胞糖代谢的研究进展. 肿瘤学杂志,2014;20(3): 947-950.
    129.陈平, 夏良平, 张蓓. 癌细胞中葡萄糖代谢与转运特点. 肿瘤学杂志,2014;20(3):244-247.
    130.尹晨希,周菲菲, 夏良平. 恶性肿瘤患者血清中PKM2水平的诊断和预后预测价值。肿瘤学杂志,2013;19(7):565-569.
    131.Xia LP, Wu PH, Xia JC, Zhang B, Guan ZZ, Wan DS, Guo GF, Zeng YX. One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.Chin J Cancer. 2010 Dec;29(12):1023-8.
    132.夏良平,郭桂芳.含西妥昔单抗方案治疗胃癌和食管癌的近期疗效.国际肿瘤学杂志,2010;37(3):217-219.
    133.夏良平,周菲菲,杨名添,等. Aurora-A在乳腺癌致瘤机制和预后方面的研究进展.癌症.2009;28(7):668-672.
    134.夏良平,周菲菲,刘强. Aurora-A激酶抑制剂的抗肿瘤作用.临床肿瘤学杂志.2009;10(10):941-945.
    135.夏良平,周菲菲,杨名添,谢小明.乳腺癌中基因标签研究的共性问题. 国际肿瘤学杂志. 2009;36(4):280-282.
    136.夏良平,周菲菲,曾宗渊. Cetuximab联合放疗和/或化疗治疗头颈癌研究进展.中华肿瘤防治杂志.2009;16(20 supple):74-77.
    137.周菲菲,夏良平,王曦.真核起始因子4E在乳腺癌中的研究进展.国际肿瘤学杂志. 2009;36(11):850-852.(通讯作者)
    138.汪芳,夏良平.Cetuximab在晚期非小细胞肺癌一线治疗中的研究进展. 肿瘤学杂志. 2011;17(9):649-652. (通讯作者)
    139.郭桂芳夏良平,姜文奇.自噬及其与结直肠癌的发生和治疗. 国际肿瘤学杂志. 2010;37(10):774-777.
    140.夏良平.喉癌诱导化疗的临床研究进展. 耳鼻咽喉-头颈外科, 2001,8(2):125-128.
    141.夏良平. 喉癌外科切缘的临床与分子生物学研究. 国外医学.肿瘤学分册,2001,28(增刊):89-91.
    142.夏良平. eIF4E作用和调节机制. 国外医学.分子生物学分册, 2001,23(5):280-282.
    143.夏良平. 声门上型喉癌N0患者颈淋巴结转移及处理. 临床耳鼻咽喉科杂志, 2001,15(12):569-571
    144.夏良平.喉癌根治性放疗失败后挽救性手术治疗. 国外医学.耳鼻咽喉科分册,2002,26(1):24-28.
    145.曾宗渊, 夏良平.鼻咽癌研究进展.肿瘤学杂志.2003,9(1):36-39.
    146.夏良平.白介素-5与嗜酸性粒细胞凋亡. 国外医学、生理、病理科学与临床分册,  1999, 19(4):301-303.

    社会任职
    1.广东省健康管理学会肿瘤防治专业委员会,主任委员
    2.广东省健康管理学会干细胞与再生医学专委会,副主任委员
    3.广东省抗癌协会靶向与个体化治疗专业委员会,常委
    4.广东省抗癌协会化疗专业委员会,委员


    更新日期:2019年9月25日
访客通道
员工通道
关注肿瘤医院
留言建议 ×
韩国电影